It appears that the numerous people living with the Parkinson’s disease are about to see a solution with the diabetes drug. The drug will not work only to curb the symptoms, but also work to prevent it from getting worse over time.
Test of exenatide and placebo
Exenatide is a medication that used to alleviate diabetes; it regulates the blood sugar levels in people with diabetes. Recently, scientists discovered its possible effectiveness in treating the Parkinson’s ailment.
The researchers from the University College London examined the drug’s efficacy in treating the Parkinson’s disease. Participants who were involved in the experiment were between 25 and 75 years of age. They were given the placebo and exenatide randomly, about 32 of the members got the exenatide drug and around 30 other persons had the placebo drug.
During the period of the study, the participants and the researchers didn’t know which drugs each of the participants were taking. After 48 weeks of therapy and 12 weeks of further study when the participants were not receiving injections, the scientists observed that the participants on exenatide showed a significant improvement in their locomotor ability. And those who were on placebo drug showed worse signs.
Exenatide shows positive effect on Parkinson’s disease
Considering the long-term ability of the drug, its effectiveness remained significant even when the medication was stopped. However, it’s not clear if the exenatide treats the ailment or just stimulate long-term symptomatic effects.
Although the researchers were not highly impressed with the results, it shows that possible evidence that can be employed in further studies. Owing to the seeming long-term effects of the drug, an extended research can give more insight into the drug’s ability to treat the cause of the Parkinson’s disease.
In line with the promising results, rechanneling the focus of this drug and another GLP-1 antagonist to treating Parkinson could be very yielding as regards positive results. Researchers advocate that a longer term research with much more participants would be worth trying. However, the scientists believe the drug may take many years before its clinically approved. As such, patients and clinicians are warned not to use this drug in treating Parkinson’s disease.
The research was possible with the assistance of Michael J. Fox Foundation for Parkinson’s Research and the Department of Health National Institute for Health Research Biomedical Research Centres. The outcome of the study is available in the Journal, The Lancet.